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ABSTRACT
The World Health Organization (WHO) classification of Tumors of Hematopoietic and 
Lymphoid Tissues (4th edition, 2008) represents an update of the 3rd edition, 2001.2 A 
summary of these changes in myeloproliferative disorders, myelodisplastic syndrome, 
acute myeloid leukemias, B and T precursor cell neoplasms, and mature B, T and NK 
cell neoplasms is presented below.  Understanding the molecular genetic changes and 
the results achieved with innovative therapeutic approaches in these groups of diseases 
require continuous reassessment of its classification, justifying the major changes dis-
cussed here1,3-5.
Keywords: World Health Organization; myelodisplatic syndromes; myeloproliferative 
disorders; lymphoproliferative disorders; classification.
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MYELOPROLIFERATIVE NEOPLASMS (MPN)
This group of neoplasms underwent considerable changes 
in this new edition. The term myeloproliferative diseases 
was replaced by myeloproliferative neoplasms (MPN), 
stressing its clonal character. The recognition of mutations/
rearrangements in protein-coding genes with tyrosine ki-
nase activity, such as BCR-ABL (chronic myeloid leukemia 
[CML]), JAK2 (polycythemia vera [PV], primary myelofi-
brosis [PMF], essential thrombocythemia [ET]), and KIT 
(mastocytosis), and of myeloid and lymphoid diseases 
concomitant with PDGFRA, PDGFRB, and FGFR1 rear-
rangements was important to define new disease groups 
and change previous diagnostic criteria. 
The major changes in MPN classification are summa-
rized as follows:
1. Mastocytosis, previously studied in a separate chap-
ter, has been included in this category, keeping the same 
classification6 .
2. Some cases that previously met the criteria for chron-
ic eosinophilic leukemia (CEL) migrated into the group of 
myeloid and lymphoid neoplasms with eosinophilia and 
abnormalities in PDGFRA, PDGFRB and FGRR1 genes. 
In the absence of either these rearrangements or the BCR-
ABL fusion, the disease belongs to the CEL category with 
no other specification.
3. The diagnostic algorithms for PV, ET and PMF were 
changed, including mutational status of JAK2 gene and 
other correlate genes. Bone marrow histological findings, 
particularly for megakaryocytes, were strengthened as di-
agnostic criteria.
4. Criteria for accelerated phase CML were maintained 
and new ones were proposed. There is still controversy re-
garding its clinical relevance in the tyrosine kinase inhibi-
tors era.
5. The platelet count threshold for ET was reduced 
from 600,000/mm3 to 450,000/mm3.
MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHI-
LIA AND ABNORMALITIES IN PDGFRA, PDGFRB, and 
FGFR1 GENES
They constitute a new group in the 2008 WHO Classi-
fication. These rare neoplasms are defined as clonal dis-
eases caused by abnormalities in genes coding for alpha 
or beta chains in receptors with tyrosine kinase activity: 
platelet-derived growth factor receptor (PDGFR) or fibro-
blast growth factor receptor (FGFR1). The relevance of 
recognizing these neoplasms is their response to tyrosine 
kinase inhibitors, particularly imatinib. Neoplasms with 
such genetic abnormalities are postulated to arise from a 
myeloid-lymphoid pluripotent progenitor cell. A frequent 
feature is eosinophilia, with these diseases being pre- 
viously known as CEL, chronic myelomonocytic leukemia 
(CMML) with eosinophilia, myeloproliferative syndrome/
myelodisplastic syndrome (MPS/MDS) with eosinophil-
ia, and hypereosinophilic syndrome. The clinical feature 
is heterogeneous, usually associated with MPN or even 
with lymphoid disease. Some cases may present as acute 
myeloid leukemia (AML), B or T cell acute lymphoid leu-
kemia (ALL), T lymphoblastic lymphoma, and disorders 
with mast cell proliferation. The most frequent gene rear-
rangement changing PDGFRA is the FIPL1-PDGFRA fu-
sion resulting from cryptic deletion of chromosome region 
4q12, detected only by molecular techniques. On the other 
hand, rearrangements in PDGFRB (located at 5q33) genes 
and FGFR1 (located at 8p11) gene can be detected by 
karyotyping or uorescence in situ hybridization (FISH) 




These diseases include clonal myeloid neoplasms that pres-
ent clinical and laboratory features of both myelodisplasia 
and myeloproliferation. While some cases of atypical BCR/
ABL-negative CMML and CML present with JAK2 muta-
tion, these diseases are better characterized by changes in 
intracellular signaling pathways RAS/MASK. To be includ-
ed in this group, the exclusion of BCR-ABL gene fusion 
and rearrangements in PDGFRA, PDGFRB, and FGFR1 
genes are required.
Other changes in this group of neoplasms include:
1. Atypical CML has been renamed BCR/ABL-negative 
atypical CML.
2. Refractory anemia with ring sideroblasts associ-
ated with thrombosis (RARS-T), also known as essential 
thrombocythemia with ring sideroblasts, was included in 
a provisional category. RARS-T diagnostic criteria include 
not further classifiable MPN/MDN criteria associated with 
RARS morphological criteria, platelet count over 450,000/
mm3, and the presence of anomalous megakaryocytes ob-
served in ET or PMF. About 60% of RARS-T has a JAK 
mutation or a MPL W515/L mutation.
MYELODYSPLASTIC SYNDROMES (MDS)
MDS are clonal disorder of hematopoietic precursor cell 
characterized by cytopenias, dysplasia in one or more my-
eloid lineages, ineective hematopoiesis, increased apop-
tosis, and an AML-prone course. The diagnostic criterion 
of < 20% blasts in bone marrow (BM) and peripheral 
blood (PB) is maintained. The dierential diagnosis be-
tween MDS and AML is strengthened when the presence 
of > 50% erythroid cells is observed in BM. The presence 
of > 20% blasts among non-erythroid cells, non-plasma 
cells, and non-lymphocytes defines AML, whereas < 20% 
blasts defines MDS. For the latter condition, the percent-
age number of blasts among all nucleate cells is again used 
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to classify MDS. Within this classification, the etiology of 
MDS with isolated del(5q) is better elucidated through the 
participation of the RPS14 gene, involved in ribosome pro-
tein function.
The main changes in the new WHO classification 
include:
1. The creation of subtype refractory cytopenia (RC) 
with dysplasia in one strain, including refractory ane-
mia, refractory neutropenia, and refractory thrombocy-
topenia, some of them previously included in the group 
of not further classifiable MDS (I/MDS). This group 
includes uni- or bicytopenias, < 5% blasts in BM, pres-
ence of dysplasia in only one lineage, and < 15% ring 
sideroblasts.
2. The refractory cytopenia with multiple lineage 
dysplasia (RC/MLD) also comprises RC/MLD with ring 
sideroblasts, since there is no difference in prognosis 
between them.
3. I/MDS diagnosis can be defined in the presence 
of three conditions: 1) presence of RC or R/MLD crite-
ria, but with 1% of blasts in PB; 2) presence of RC with 
pancytopenias; and 3) presence of persistent citopenias 
with < 1% of blasts in PB and < 5% in BM, dysplasia in 
< 10% of cells in one or more myeloid lineages and cy-
togenetic abnormalities associate with MDS.
4. Inclusion of pediatric MDS (P-MDS) and a provi-
sional category, childhood refractory cytopenia (P-RC). 
For children with 2% to 19% blasts in PB and 5% to 19% 
blasts in BM, the same criterion as for RAEB is used, as 
in adults. As for RC-P, comprising about 50% of P-MDS 
cases, it is characterized by persistent citopenias, < 5% 
blasts in BM and < 2% in PB, associated with dysplasias 
and marrow hypocellularity in 75% of cases. The dif-
ferential diagnosis between hypoplastic P-RC and bone 
marrow aplasia is difficult and particularly based on as-
pirate dysplasias and BM histology.
ACUTE MYELOID LEUKEMIA (AML) AND RELATED-PRE-
CURSOR NEOPLASM
In order to consider a leukemia diagnosis, blasts must 
correspond to more than 20% in the differential count 
of 200 cells in PB or 500 cells in BM. In the 2008 WHO 
classification, genetic changes were incorporated into 
AML diagnostic algorithms.
AML WITH RECURRENT GENETIC ABNORMALITIES:
Leukemias with recurrent genetic abnormalities cod-
ing for transcription factors and encompassing AML 
with t(8;21) or ETO/AML1 (currently termed RUNX1/
RUNX1T1), t(15;17) or PML/RARA, inv(16) or CBFB/
MYH11 and 11q23 or MLL were given well-defined new 
elements described below. Discovering the importance 
of mutated genes (KIT, FLT3, MLL, CEBP, NPM1, WT1, 
BAALC, ERG, and MN1) in leukemogenesis allowed 
AML subtype characterization of AML with normal 
karyotype, enabling their designation as specific enti-
ties. In this setting, the most important changes were 
as follows:
1. AMLs with recurrent genetic abnormalities, such 
as t(8;21) (q22;q22), inv(16)(p13.1q22) or t(16;16)
(p13.1;q22) and promyelocytic leukemia (PML) with 
t(15;17)(q22;q12), are considered leukemia regardless 
the blast percentage in peripheral blood or bone marrow.
2. The so-called variant PMLs, i.e., with trans-
locations involving other chromosomes, such as, 
11q23(ZBTB16), 11q13(NuMA), 5q35(NPM) or 
17q11.2(STAT5B) should be designated with the spe-
cific partner. Not all of them are responsive to ATRA or 
have a typical morphology.
3. ALM with 11q23 or MLL change was reviewed 
and ALM with t(9;11)(p22;q23) or MLLT3/MLL, which 
is the most frequent, will be so designated. The other 
changes involving 11q23 with over 80 partners are still 
termed MLL abnormalities. However, it is recommend-
ed that variant translocations should also be specified. 
Other abnormalities, such as partial tandem duplica-
tion, are not allocated in this category.
4. Three new cytogenetic entities were added since 
they presented different morphology and clinical be-
havior: a) AML with t(6;9)(p23;q34) or DEK/NUP214; 
b) AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) or 
RPN1/EVI1; and c) megakaryoblastic ALM with t(1;22)
(p13;a13) or RB<15/MKL1.
5. Two provisional categories were incorporated: 
AML with mutated NPM1 and AML with mutated CEB-
PA. Even though FLT3 mutation has not been included 
into a provisional category, this mutation assessment is 
recommended in all cases of normal karyotype AML.
AML WITH MYELODYSPLASIA-RELATED CHANGES
Regarding AML with multiple lineage dysplasia initially 
introduced in the classification to incorporate AML 
with dysplasic characteristics, unfavorable karyotype, 
increased expression of multiple drug resistance (MDR) 
glycoprotein, and poor response to chemotherapy, it is 
now termed AML with myelodysplasia-related changes. 
For this purpose, criteria have been expanded to include 
a history of previous myelodysplasic (MDS) or myelo-
dysplasic/myeloproliferative (MDS/MPS) syndrome. 
Over 20% of blasts must be found in PB or BM, it must 
have progressed from MDS or MDS/MPS previously 
documented, show chromosome changes specifically 
related to MDS and exhibit dysplasia in 50% or more in 
two myeloid lineage cells. If karyotype is normal, FLT3, 
NMP1, and CEPBA mutations must be investigated; if 
present, they must be reported in the diagnosis.
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THERAPY-RELATED MYELOID NEOPLASMS (T-MN)
Regarding therapy-related myeloid neoplasm, previously 
encompassing AML, MDS, and MDS/MPS, it now presents 
as a single AML subgroup. T-AML, T-MDS, and T-MDS/
MPS must be considered, from the biologic point of view, 
as a single entity. There is no longer a recommendation 
to dierentiate between them according to the therapeu-
tic agent used, i.e., radiation therapy, alkylating agent or 
topoisomerase II inhibitor, as previously required. Despite 
the chromosome changes in cases of neoplasms secondary 
to therapy are practically identical to the myelodysplasia-
related AML changes, the former have, as a rule, worse 
outcome than the latter with the same cytogenetic change. 
This fact suggests they are biologically dissimilar diseases.
AML NOT OTHERWISE SPECIFIED (AML, NOS)
AML, NOS, which includes all cases that did not meet cri-
teria for the other categories, became empty as other sub-
groups have been recognized. A number of erythroid or 
megakaryobplastic leukemia cases can now be reclassified 
as AML with myelodysplasia-related changes. The option 
was to keep the leukemia name, according to the morpho-
logical, cytochemical, and immunophenotypic character-
istics of the afiected cell. For this subgroup, more than 20% 
blasts in PB or BM are required, except for acute erythroid 
leukemia, which is based on abnormal erythroblasts per-
centage for pure erythroid and on myeloblast percentage 
permeating non-erythroid cells for erythroid/myeloid 
type. The promonocytes in leukemia with monocytic dif-
ferentiation are considered as blasts in the counting.
THREE NEW MYELOID ENTITIES HAVE BEEN CONSIDERED
1. Myeloid sarcoma, previously termed granulocytic 
sarcoma or chloroma, consists of extramedullary blasts 
proliferation from one or more myeloid lineages, replacing 
the original tissue normal architecture.
2. Myeloid proliferations related to Down syndrome 
comprise abnormal transient myelopoiesis and myeloid leu-
kemia, showing peculiar morphology, immunophenotype, 
clinical, and molecular features with GATA1 mutation.
3. Blastic plasmocytoid dendritic cell neoplasm, de-
fined as derived from plasmocytoid dendritic cell precur-
sors; it was previously recognized either as NK blastic cell 
lymphoma or CD4+/CD56+ hematodermic neoplasm. It is 
a neoplasm considered now among myeloid neoplasms, 
being clinically aggressive and characterized by skin dam-
age associated with regional lymphadenopathy.
ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE
The new version or the WHO, 2008, allocates these dis-
eases to a separate chapter and changes diagnostic criteria. 
Thus, cases with no specific lineage markers are termed 
undifierentiated acute leukemia, usually expressing CD34, 
HLA-Dr and/or CD38 and sometimes TdT, but they do 
not express specific myeloid or lymphoid antigens. The 
leukemias whose blasts express concomitantly antigens 
from more than one lineage in the same cell or have dis-
tinct blast populations from difierent lineages are termed 
mixed phenotype acute leukemias.
A provisional entity was created, a lymphoblastic leu-
kemia/lymphoma of  NK cells. The majority of cases pre-
viously recognized as blastic NK cell lymphoma/leukemia 
are now termed blastic plasmocytoid dendritic cell neo-
plasm, as mentioned above. Although the neoplasm phe-
notype of true NK cell precursors is not clear, the diagnosis 
should be considered when blasts express CD56 with an-
tigens associated with immature T cell, such as CD7 and 
CD2, in the absence of any B expression or myeloid an-
tigen and with no rearrangement of T cell receptor gene.
LYMPHOID PRECURSOR NEOPLASMS: B LYMPHOBLASTIC 
LEUKEMIA/LYMPHOMA AND T LYMPHOBLASTIC LEUKEMIA/
LYMPHOMA
The designation B precursor leukemia/lymphoma was 
replaced by B lymphoblastic leukemia/lymphoma, with 
caution being exerted at incorporating genetic changes. 
Next, the convention used for therapeutic approach to 
distinguish lymphoma from leukemia, considering the 
presence of tumor mass accompanied by 25% or more 
nucleolate cells in bone marrow (lymphoblasts) is con-
sidered as acute lymphoblastic leukemia rather than lym-
phoma. On the other hand, as an ALL rarely shows low 
lymphoblast percentage, if there are < 20% blasts, ALL 
diagnosis should be postponed until irrefutable evidence 
confirms the diagnosis. Furthermore, in a rare circum-
stance when there are < 20% blasts in bone marrow, in the 
absence of chromosome change, but in the presence of re-
current chromosome change associated with ALL, the di-
agnosis of ALL could be considered, since the search for 
extramedullary mass has been exhaustive in order to rule 
out lymphoblastic lymphoma. Attention is drawn also to 
the detail that the designation of B-ALL must not be used 
for Burkitt’s lymphoma, which is a neoplasm of mature B 
cell. Given the fact that several chromosome abnormali-
ties define clinical, immunophenotypic, and prognostic 
features, they are now considered distinguished entities, 
e.g., ALL/lymphoma with t(1;19)(q23;p13.3), TCRF3/
PBX1 etc. In this setting, ALL cases in children with nor-
mal karyotype should be complemented by investigating 
t(12;21)(p13;q22) by fiuorescence in situ hybridization 
(FISH)or ETV6/RUNX1 rearrangement undetectable 
by classical cytogenetics, as this abnormality identifies 
a favorable prognosis. Similarly, all the patients should 
be assessed for Philadelphia chromosome presence and/
or BCR/ABL1 rearrangement in view of their poor prog-
nosis. Cases with eosinophilia should be additionally in-
vestigated for t(5;14)(q31;q32) or IL3/IGH, as they can 
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have low blast percentage, and this chromosome abnor-
mality is enough to diagnose ALL. Moreover, when faced 
with eosinophilia, FGFR1 rearrangements should also be 
sought, which, if present, describe the diagnosis of leu-
kemia/lymphoblastic lymphoma associated with FGFR1 
rearrangement.
In the absence of any cytogenetic or molecular change 
aer comprehensive analysis, ALL is classified as B lym-
phoblastic leukemia/lymphoma with no other specifica-
tion. T lymphoblastic leukemia/lymphoma shows fre-
quent chromosome rearrangements involving 14q11.2, 
7q35, 7p14-15, loci of alpha, beta, and gamma T cell re-
ceptors, respectively. As the pathogenetic significance of 
such abnormalities is not clear yet, this leukemia subtype 
is not subclassified according to the genetic change.
MATURE B CELL NEOPLASMS
1. Chronic lymphoid leukemia (CLL)/lymphocytic 
lymphoma – the criteria for diagnosing CLL were re-
viewed according to the International Workshop on CLL7 .
– The diagnosis of CLL, in the absence of extramed-
ullary involvement, requires > 5 x 109 B cells/L with CLL 
immunophenotype in PB. Patients with low level of lym-
phocytosis persisting for three months and accompanied 
by cytopenia or symptoms related to the disease also can 
be concluded as CLL.
– The term LL is used in cases with CLL tissue mor-
phology and immunophenotype, enlarged lymph nodes 
without cytopenia due to infiltration by CLL and < 5 x 109 
B cells/L in PB.
– The category of monoclonal B lymphocytosis is rec-
ognized and defined as the presence of monoclonal B lym-
phocyte in PB with immunophenotype in most cases of 
CLL, but without CLL criteria. This entity clinical signifi-
cance has not been defined yet.
2. Among splenic lymphomas, the not further classifi-
able B cell lymphoma/leukemia category has been intro-
duced, including two rare provisional entities, the splenic 
diThuse red pulp small B-cell lymphoma and the hairy-cell 
leukemia variant, whose relationship between themselves 
and between them and the splenic lymphoma with villous 
lymphocytes still needs to be better defined. The term not 
further classifiable B-cell lymphoma/leukemia must be 
used for the small B-cell lymphomas showing neither the 
criteria for the above entities nor the criteria for any other 
classical small B-cell lymphoma.
– Splenic diThuse red pulp small B-cell lymphoma is 
considered synonymous with a less specific entity termed 
splenic lymphoma with villous lymphocytes, with some 
overlapping with hairy-cell leukemia variant.
– Hairy-cell leukemia variant only changes position in 
the classification, as it is no longer considered biologically 
related to hairy-cell leukemia.
3. Lymphoplasmacytic lymphoma (LPL) – diagnosis 
criteria have not been changed, but the diagnosis of small 
B-cell lymphomas with plasmacytic diTherentiation, fol-
lowed by possible diTherential diagnosis in those circum-
stances when LPL criteria are not met or for the classi-
cal entities in the small B-cell lymphoma group showing 
plasmacytic diTherentiation is recommended. Regarding 
Waldenström macroglobulinemia (WM), according to 
the International Workshop on WM, 20028 , it is now de-
fined as LPL with BM involvement and monoclonal gam-
mopathy at any serum level.
4. The nodal marginal zone lymphoma loses “B-cell” 
and pediatric cases are separately classified, since they are 
usually localized, having an excellent prognosis.
5. Follicular lymphoma (FL) – regarding histological 
grading, the criteria remain the same, but grades 1 and 
2 are now considered together as low level. Regarding 
grade 3, the criteria remain for 3A and 3B. Focal grade 
3 areas in a low level FL should be reported and semi-
quantified when the diagnosis is made. In a grade 3 FL 
(A or B), the presence of a diThuse component (may be 
confirmed by CFD absence through CD21 or CD23) de-
serves an additional separate diagnosis of diThuse large 
B-cell lymphoma (DLBCL), estimating its ratio. DLBCL 
areas are found in 60% to 80% of FL-3B, being less fre-
quent in FL-3A. FL variants are recognized, including:
– Pediatric FL – characteriscally BCL2-negative, 
t(11;14)BCL2/IGH-negative and oThen grade 3, but with 
a favorable course.
– Primary FL of the gastrointestinal tract – oThen in 
duodenum, similar to node FL, usually localized, with a 
good outcome even if untreated.
– In situ follicular neoplasm – CD10+/BCL2 center-
cell populations in varying proportions inside some fol-
licle germinal centers  – their clinical significance is still 
unclear.
6. Primary cutaneous follicle center lymphoma – 
appears as a separate entity, included since the WHO-
EORTC classification9 .
7. Mantle cell lymphoma (MCL) – diagnostic crite-
ria are still the same, but a broad clinical spectrum is as-
sumed with more indolent cases, particularly with pre-
dominant BM and PB involvement. An in situ MCL form, 
with nuclear clinical and biological significance, has been 
described. At the other extreme of the clinical spectrum 
there are the aggressive variants termed blastoid (similar 
to the lymphoblastic lymphoma) and pleomorphic (simi-
lar to DLBCL). A cell proliferation assessment through 
mitosis count or Ki-67+ cell ratio is considered a prog-
nosis factor relevant although having no definite cut-oTh.
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8. Diuse large B-cell lymphoma (DLBCL) – a long list 
of new DLBCL entities and subtypes particularly related to 
specific sites and the association with virus (EBV and/or 
HHV8) is introduced; these virus have frequent morpho-
logic and immunophenotypic characteristics of terminal 
(plasmablastic) B-cell dierentiation.
MATURE T- AND NK-CELL NEOPLASMS
The 2008 WHO  classification for T/NK neoplasms brought 
information regarding diagnostic criteria, etiology, and 
prognosis in this large neoplasm group. In a didactic way, T/
NK neoplasms will be presented in four groups: 1) Predom-
inantly nodal T lymphomas; 2) Extranodal T/NK lympho-
mas; 3) Cutaneous T/NK lymphomas; and 4) Predominant-
ly leukemic presentation T/NK lymphomas. For a summary 
on the major changes in T-cell neoplasms (Table 1).
1. Predominantly nodal presentation T lymphomas
The largest group of T lymphomas, the so-called periph-
eral T-cell lymphomas not otherwise specified underwent 
few changes. The most subtle regards a change from un-
specified to not otherwise specified. The variants T zone 
lymphoma and the lymphoepithelioid lymphoma (Lenne-
rt’s lymphoma) were maintained, with the follicular vari-
ant being incorporated. This latter variant can simulate the 
nodular pattern B-cell lymphomas (FL, MZL, and MCL) 
and would originate in T-cell follicular helper (TFH), as 
would the angioimmunoblastic T-cell lymphomas (AITL) 
(see below).
The anaplastic large cell lymphomas (ALCL) have 
been subdivided into ALK-positive and ALK-negative. 
This makes this protein expression assessment mandatory. 
The ALCL/ALK-negative lymphomas have worse prog-
nosis than the ALCL/ALK-positive lymphomas, though 
their outcome is still superior to that of peripheral T-cell 
lymphomas NOS. The ALCL/ALK-negative lymphomas 
diagnosis implies the presence of classical morphology, 
cytotoxic cells, less frequent EMA expression, and more 
frequent T markers expression. In ALCL/ALK-positive 
lymphomas, the criteria remained the same, with a new 
variant addition (Hodgkin-like, similar to nodular sclero-
sis) to recognized variants (small cell and e lympho-his-
tiocytic).
Finally, the ALCL was maintained with the same no-
menclature and diagnostic criteria, being recorded the rec-
ognition of its origin cell as a specific CD4+ cell population 
designated TFH (T-cell follicular helper). Typical markers 
of these cells, such as cytokine CXCL13, PD1 protein (pro-
gram death 1), and CD10 can be used in these lymphomas 
identification.
2. T/NK-cell neoplasms predominantly extranodal
Few changes were introduced in this group of lymphomas, 
with the same four entities being maintained: entheropa-
thy-associated T-cell lymphoma, subcutaneous panniculi-
tis-like T-cell lymphoma, hepatosplenic T-cell lymphoma, 
and extranodal T/NK-cell lymphoma, nasal type. The lat-
ter two (hepatosplenic and nasal types) were maintained 
practically unchanged.
The subcutaneous panniculitis-like T-cell lymphoma, in 
the 2008 WHO classification, has not included those with gd 
T cells origin, which will be included with cutaneous lym-
phomas (see below). What is new in this classification for 
these lymphomas is the recognition that these neoplasms 
are associated with autoimmune disorders (specially lupus 
erythematosus) and share similarities with deep lupus pan-
niculitis. The cells are CD8+ expressing granzyme B, perfo-
rin and bF1. In contrast, the cutaneous gd T-cell lymphoma 
does not express CD56; hemophagocytosis is observed in 
less than 20% of cases and is accompanied by a better prog-
nosis.
The entheropathy-associated T-cell lymphomas were 
subdivided in type I (classical) and type II (monomorphic), 
both with poor prognosis. The classical type corresponds to 
the great majority of cases and is usually associated with ce-
liac disease, with varying histological and clinical presenta-
tion. Most cells are large, there is an accompanying inTham-
matory infiltrate and the cells present CD3+/CD5-/CD7+//
CD4-CD8-20%+/CD103+/granzyme/perforin+CD30± 
immunophenotype. The type II or monomorphic type rep-
resents less than 20% of total cases; it has a more uniform 
histopathological presentation and shows a diTherent im-
munophenotypic profile CD8+/CD56+. The entheropathy-
associated T-cell lymphoma is still recognized in its in situ 
form, characterized by clonal intraepithelial lymphocytes, 
manifesting clinically as either a celiac disease refractory to 
gluten withdrawal or an ulcerative jejunitis.
3. T/NK-cell lymphomas with cutaneous presentation
The cutaneous T/NK-cell lymphomas are classified as my-
cosis fungoides, Sézary syndrome, CD30-positive T-cell 
lymphoproliferative disorders, cutaneous gd T-cell lympho-
ma, and two provisional entities, CD8+aggressive epider-
motropic cytotoxic T-cell lymphoma and cutaneous CD4+ 
small/medium T-cell lymphoma.
The definitions of mycosis fungoides and Sézary syn-
drome were not changed. The lymph node classification was 
better characterized, defining more precisely the categories 
N1 (dermatopathic lymphadenopathy with atypical cell 
clusters – between three and six cells), N2 (dermatopathic 
lymphadenopathy with scarce cerebriform cells < 7.5 mm 
and architecture maintained) and N3 (evident neoplastic in-
volvement, even if it is partial). The clinical staging was also 
changed, and new pathogenetic factors were defined.
The CD30+ T-cell lymphoproliferative disorders include 
cutaneous primary ALCL, lymphomatoid papulosis, and bor-
derline cases. Significant changes in diagnostic criteria for these 
entities were not observerd, with three histological subtypes 
being recognized (A, B, and C) for lymphomatoid papulosis.
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Table 1 – Major changes introduced into the T/NK-cell neoplasm group in the 2008 WHO classification
The cutaneous gd T-cell lymphoma has already been 
noted and it was separated from panniculitis-like lympho-
mas. Much more oen, these lymphomas aect the sub-
cutaneous cellular tissue, but they do not spare the der-
mis and the epidermis, with epidermotropic, dermic and 
predominantly subcutaneous subtypes being recognized. 
Necrosis, angioinvasion and hemophagocytosis are oen 
observed.
Two rare provisional entities were included. The first 
one is the cutaneous CD8+ aggressive epidermotropic cy-
totoxic T-cell lymphoma, characterized by an aggressive 
course with necrosis and skin ulceration. The second en-
tity is the cutaneous CD4+ small/medium T-cell lympho-
ma, with excellent prognosis. The dierential diagnosis 
between these entities and reaction processes is di cult, 
since they are associated with a plasma cell and B-lympho-
cyte infiltrate. The main diagnostic criteria are T antigen 
loss and clonal TCR clonal rearrangement. They are both 
entities whose molecular defects are unknown.
Finally, the blastic NK-cell lymphoma is excluded from 
this group and will be recognized as plasmocytoid den-
dritic cell neoplasm, as previously mentioned.
4. T/NK-cell neoplasms with predominantly leukemic 
presentation
The only significant change was the inclusion of chronic 
lymphoproliferative disorder of NK-cells as a provisional 
entity, characterized by chronic and indolent increase in 
NK-cell count, with di cult dierential diagnosis using 
rational processes.
2001 WHO 2008 WHO Comments
Angioimmunoblastic Lymphoma Angioimmunoblastic Lymphoma Definition of origin cell
Anaplastic Large Cell Lymphoma 2 variants based on ALK (+/-) expression Prognostic importance
Unspecified Peripheral T-cell Lymphoma Peripheral T-cell Lymphomas not 
Otherwise Specified
3 variants: lymphoepitelioid lymphoma, 
T zone lymphoma (2001 WHO) and 
follicular lymphoma (2008 WHO)





Two variants: classical and monomorphic 
types with genetic changes common to 
both
Hepatosplenic T-cell lymphoma Hepatosplenic T-cell lymphoma No changes
Subcutaneous panniculitis-like T-cell 
lymphoma
Subcutaneous panniculitis-like T-cell 
lymphoma
Only ab and associated with 
autoimmune disorder
Mycosis fungoides Mycosis fungoides New staging and new information about 
pathogenesis
Sézary syndrome Sézary syndrome New markers
Primary cutaneous anaplastic large cell 
lymphoma
Primary cutaneous anaplastic large cell 
lymphoma
Recognition of CD8+ cases
Lymphomatoid papulosis Lymphomatoid papulosis Three histological types
Primary cutaneous gamma-delta T-cell 
lymphoma
Three histopathologic patterns: 
epidermotropic, dermic, and 
subcutaneous subtypes
Primary cutaneous CD8+ aggressive 
epidermotropic cytotoxic T-cell 
lymphoma
Provisional entity
Primary cutaneous CD4+ small/medium 
T-cell lymphoma
Provisional entity
Blastic NK-cell lymphoma Plasmocytoid dendritic cell neoplasm Now it is one of the myeloid neoplasms
T-cell prolymphocytic leukemia T-cell prolymphocytic leukemia No changes
T-cell large granular lymphocytic 
leukemia
T-cell large granular lymphocytic 
leukemia
New etiological features and new 
markers
Chronic lymphoproliferative disorder of 
NK-cells
Provisional entity
Aggressive NK-cell leukemia Aggressive NK-cell leukemia No changes
Adult T-cell leukemia/lymphoma Adult T-cell leukemia/lymphoma Definition of the regulatory T-cell normal 
counterpart
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